167 related articles for article (PubMed ID: 36259862)
1. A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination.
Daines B; Madigan LM; Vitale PA; Khalighi M; Innes M
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259862
[TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
[TBL] [Abstract][Full Text] [Related]
3. Bullous Pemphigoid Developed after the COVID-19 Vaccine.
Linares-Navarro R; Ramírez GR; Perandones-González H; Rodríguez-Prieto MÁ
Skinmed; 2023; 21(3):200-202. PubMed ID: 37634107
[TBL] [Abstract][Full Text] [Related]
4. Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination.
Birabaharan M; Kaelber DC; Orme CM; Paravar T; Karris MY
Br J Dermatol; 2022 Aug; 187(2):271-273. PubMed ID: 35279833
[No Abstract] [Full Text] [Related]
5. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination.
Tomayko MM; Damsky W; Fathy R; McMahon DE; Turner N; Valentin MN; Rallis T; Aivaz O; Fox LP; Freeman EE
J Allergy Clin Immunol; 2021 Sep; 148(3):750-751. PubMed ID: 34275656
[No Abstract] [Full Text] [Related]
6. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination.
Fu PA; Chen CW; Hsu YT; Wei KC; Lin PC; Chen TY
J Formos Med Assoc; 2022 Sep; 121(9):1872-1876. PubMed ID: 35321820
[TBL] [Abstract][Full Text] [Related]
7. Rapidly progressing generalized bullous fixed drug eruption after the first dose of COVID-19 messenger RNA vaccination.
Choi S; Kim SH; Hwang JH; Jang HW; Oh SH; Kim DY; Kim TG
J Dermatol; 2023 Sep; 50(9):1190-1193. PubMed ID: 37102209
[TBL] [Abstract][Full Text] [Related]
8. Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to 'Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review' by Pauluzzi et al.
Martora F; Ruggiero A; Battista T; Fabbrocini G; Megna M
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e35-e36. PubMed ID: 35974447
[No Abstract] [Full Text] [Related]
9. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination.
Larson V; Seidenberg R; Caplan A; Brinster NK; Meehan SA; Kim RH
J Cutan Pathol; 2022 Jan; 49(1):34-41. PubMed ID: 34292611
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study.
McMahon DE; Kovarik CL; Damsky W; Rosenbach M; Lipoff JB; Tyagi A; Chamberlin G; Fathy R; Nazarian RM; Desai SR; Lim HW; Thiers BH; Hruza GJ; French LE; Blumenthal K; Fox LP; Freeman EE
J Am Acad Dermatol; 2022 Jan; 86(1):113-121. PubMed ID: 34517079
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review.
Pauluzzi M; Stinco G; Errichetti E
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e257-e259. PubMed ID: 34928518
[No Abstract] [Full Text] [Related]
12. Bullous pemphigoid after inactivated COVID-19 vaccination: Case report.
Zhang Y; Lang X; Guo S; He H; Cui H
Dermatol Ther; 2022 Aug; 35(8):e15595. PubMed ID: 35608483
[No Abstract] [Full Text] [Related]
13. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.
Kong J; Cuevas-Castillo F; Nassar M; Lei CM; Idrees Z; Fix WC; Halverstam C; Mir A; Elbendary A; Mathew A
J Infect Public Health; 2021 Oct; 14(10):1392-1394. PubMed ID: 34294590
[TBL] [Abstract][Full Text] [Related]
14. Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination.
Hung WK; Chi CC
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e407-e409. PubMed ID: 35073431
[No Abstract] [Full Text] [Related]
15. New-onset bullous pemphigoid and flare of pre-existing bullous pemphigoid after the third dose of the COVID-19 vaccine.
Bardazzi F; Carpanese MA; Abbenante D; Filippi F; Sacchelli L; Loi C
Dermatol Ther; 2022 Jul; 35(7):e15555. PubMed ID: 35510556
[No Abstract] [Full Text] [Related]
16. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
17. Dermatopathology of COVID-19 infection and vaccination.
Fernández-Figueras MT
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):114-118. PubMed ID: 36197514
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
19. Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
Sun L; Brazão C; Mancha D; Soares-de-Almeida L; Filipe P
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e578-e580. PubMed ID: 36681888
[No Abstract] [Full Text] [Related]
20. A Bullous Eruption following the Pfizer-BioNTech COVID-19 vaccination.
D'Cruz A; Parker H; Saha M
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e864-e865. PubMed ID: 34416058
[No Abstract] [Full Text] [Related]
[Next] [New Search]
